Skip to content

2020 November 12 release

Pre-release
Pre-release
Compare
Choose a tag to compare
@brendanreardon brendanreardon released this 07 Jan 21:54
· 64 commits to main since this release
v.2020-11-12
99e1c3f

This release focuses on FDA approvals since March 2020. In addition to the following changes, the citation style for all FDA approved associated have been updated to match American Medical Association (AMA) style formatting.

Added entries:

  • (FDA) ATM somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) BARD1 somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) BRAF p.V600K, p.V600E associated with sensitivity to encorafenib in melanoma.
  • (FDA) BRAF p.V600E associated with sensitivity to cetuximab + encorafenib in colorectal cancer.
  • (FDA) BRCA1 and BRCA2 somatic and germline variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) BRCA1 and BRCA2 somatic and germline variants associated with sensitivity to niraparib in ovarian, fallopian tube, and peritoneal cancer.
  • (FDA) BRCA1 and BRCA2 somatic variants associated with sensitivity to bevacizumab and olaparib in advanced ovarian, fallopian tube, and peritoneal cancer.
  • (FDA) BRIP1 somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) CD274 copy number amplifications associated with sensitivity to atezolizumab in non-small cell lung cancer.
  • (FDA) CDK12 somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) CHEK1 and CHEK2 somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) ERBB2 copy number amplifications associated with sensitivity to capecitabine + trastuzumab + tucatinib in breast cancer.
  • (FDA) ERBB2 copy number amplifications associated with sensitivity to chemotherapy + hyaluronidase-zzxf + pertuzumab + trastuzumab in breast cancer.
  • (FDA) ERBB2 copy number amplifications associated with sensitivity to docetaxel + hyaluronidase-zzxf + pertuzumab + trastuzumab in metastatic breast cancer.
  • (FDA) EZH2 p.Y646*, p.Y646F, p.Y646N, p.A682G, and p.A692V associated with sensitivity to tazemetostat in relapsed or refractory follicular lymphoma.
  • (FDA) FANCL somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) FGFR2 fusions associated with sensitivity to pemigatinib in cholangiocarcinoma.
  • (FDA) High-TMB (> 10 coding mutations per Mb) associated with sensitivity to pembrolizumab in any unresectable or metastatic solid tumor.
  • (FDA) MET somatic splice site, deletion, and nonsense variants associated with sensitivity to capmatinib and crizotinib in non-small cell lung cancer.
  • (FDA) PALB2 somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) RAD51B, RAD51C, RAD51D, and RAD51L somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
  • (FDA) RET fusions associated with sensitivity to pralsetinib in non-small cell lung cancer.
  • (FDA) RET somatic variants associated with sensitivity to selpercatinib in medullarly thyroid cancer.
  • (FDA) RET fusions associated with sensitivity to selpercatinib in non-small cell lung cancer and thyroid cancer.
  • (Inferential) COSMIC Signature 3, associated with Homologous Recombination Deficiency (HRD), associated with sensitivity to bevacizumab and olaparib in advanced ovarian, fallopian tube, and peritoneal cancer.

Edited entries:

  • (Clinical trial) ATM frameshift, nonsense, and splice site somatic variants associated with sensitivity to BAY1895344 in any solid tumor. Updated disease context from "Advanced metastatic" to "Advanced or metastatic".
Assets 2
Loading